Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$75,900.00-1.51%ETH$2,404.54-3.20%GOLD$4,387.30+1.26%OIL$103.71-2.00%
Smart Investors Daily
LY

NASDAQ · LYEL

Lyell Immunopharma, Inc.

Healthcare · Biotechnology

$10.91

Down-$0.42 (-3.71%)

Updated Sep 16, 2026, 11:08 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
708.04M
P/E ratio
-1.87
Dividend yield
0.00%
52-week range
$11.24 – $45.00
Volume
184.15K
Avg. volume
48.46K

Price performance

LYEL price history

1M range · 20 trading sessions · Daily adjusted prices

LYEL closed at $10.91 after 20 trading sessions, down 30.91% for the selected period.

Last close
$10.91
Period change
-30.91%
Period low
$10.91
Period high
$15.79
Daily close
View OHLC price history
LYEL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$11.29$11.29$10.55$10.91184.15K
Sep 14, 2026$11.97$12.385$11.24$11.33104.41K
Sep 11, 2026$12.41$13.00$11.70$11.96152.2K
Sep 10, 2026$12.70$12.71$12.04$12.20111.12K
Sep 9, 2026$13.52$13.82$12.71$12.88101.57K
Sep 8, 2026$14.12$14.13$13.37$13.5383K
Sep 4, 2026$14.29$14.68$13.92$14.3754.07K
Sep 3, 2026$15.11$15.14$14.19$14.3279.05K
Sep 2, 2026$14.49$14.97$14.25$14.95556.86K
Sep 1, 2026$14.14$14.835$14.00$14.52567.01K
Aug 31, 2026$14.51$14.71$14.14$14.3262.77K
Aug 28, 2026$14.56$14.78$14.06$14.5378.12K
Aug 27, 2026$14.67$15.02$14.33$14.6188.38K
Aug 26, 2026$15.34$15.4102$14.61$14.8087.78K
Aug 25, 2026$15.02$15.68$14.92$15.49103K
Aug 24, 2026$15.30$15.49$14.46$14.7473.24K
Aug 21, 2026$15.54$16.1599$15.20$15.53104.91K
Aug 20, 2026$15.59$16.015$14.525$15.35207.67K
Aug 19, 2026$16.02$17.15$15.66$15.76171.05K
Aug 18, 2026$13.54$15.81$13.46$15.79311K

Latest LYEL news

The latest Smart Investors Daily articles mentioning LYEL.

Stock researchCompany · Overview

LYEL research

Overview

Company profile and research snapshot.

Company profile

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$45.00
Implied upside
—
Analysts
—
LYEL recent ratings
DateFirmRatingTarget
Sep 11, 2026NeedhamBuy—
Aug 6, 2026StifelBuy—
Jul 22, 2026B. Riley SecuritiesBuy—
Jun 15, 2026CitizensMarket Outperform—
Jun 15, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 6, 2026

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

PiNACLE pivotal clinical trial evaluating ronde-cel in 3L+ patients with LBCL on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission expected to follow in the second half of 2027Presented updated ronde-cel data in more than 100 patients with relapsed/refractory LBCL at the EHA 2026 Congress, with Phase 1/2 safety data showing no Grade ≥ 3 CRS and low rates of Grade ≥ 3 ICANS supporting potential outpatient administrationReported updated

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By